Cytokinetics(CYTK) - 2023 Q3 - Earnings Call Transcript

Thank you. [Operator Instructions] And our first question will come from Joe Pantginis from H.C. Wainwright. Your line is open. Joe Pantginis Robert Blum Thanks Joe. I think with regard to withdrawal of background therapy, the protocol, as we reported back at ACC allows investigators to will solely withdraw beta blockers or other background therapies such as disopirmide or calcium channel blockers based on patient tolerance. So, I think from a patient point of view, it simplifies medical therapy. It gets th ...